We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
+$27.8M
Cap. Flow %
7.12%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQ icon
101
Equillium
EQ
$139M
$429K 0.11%
+300,000
New +$317K
ALEC icon
102
Alector
ALEC
$168M
$403K 0.1%
136,023
-130,000
-49% -$286K
CRVS icon
103
PUT
Corvus Pharmaceuticals
CRVS
$1.12B
$369K 0.09%
+50,000
New +$256K
VTGN icon
104
CALL
VistaGen Therapeutics
VTGN
$10.1M
$356K 0.09%
100,200
+100,000
+50,000% +$299K
PRQR icon
105
ProQR Therapeutics
PRQR
$241M
$336K 0.09%
157,694
– –
PYXS icon
106
Pyxis Oncology
PYXS
$193M
$333K 0.09%
+150,000
New +$216K
CCCC icon
107
CALL
C4 Therapeutics
CCCC
$387M
$312K 0.08%
+140,700
New +$338K
PTHS
108
Pelthos Therapeutics
PTHS
$93.3M
$294K 0.08%
+10,498
New +$255K
RARE icon
109
Ultragenyx Pharmaceutical
RARE
$2.46B
$276K 0.07%
9,189
-44,796
-83% -$1.34M
CLYM
110
Climb Bio
CLYM
$676M
$274K 0.07%
136,488
-565,647
-81% -$1.05M
NEUP
111
Neuphoria Therapeutics
NEUP
$21.2M
$253K 0.06%
+21,452
New +$199K
FHTX icon
112
Foghorn Therapeutics
FHTX
$271M
$245K 0.06%
+50,000
New +$265K
OVID icon
113
Ovid Therapeutics
OVID
$435M
$244K 0.06%
+187,739
New +$163K
RLAY icon
114
Relay Therapeutics
RLAY
$4.09B
$228K 0.06%
43,616
– –
VTYX
115
DELISTED
Ventyx Biosciences
VTYX
$221K 0.06%
+71,204
New +$189K
MLTX icon
116
CALL
MoonLake Immunotherapeutics
MLTX
$1.48B
$187K 0.05%
+26,100
New +$1.36M
PRTC
117
DELISTED
PureTech Health
PRTC
$135K 0.03%
7,324
– –
RCEL icon
118
CALL
Avita Medical
RCEL
$142M
$128K 0.03%
+25,100
New +$131K
ANAB icon
119
AnaptysBio
ANAB
$1.59B
$101K 0.03%
+3,295
New +$75.6K
ATYR
120
CALL
aTyr Pharma
ATYR
$48.2M
$92.8K 0.02%
128,700
– –
TVRD
121
Tvardi Therapeutics
TVRD
$19M
$85.1K 0.02%
+2,185
New +$62.2K
MREO
122
PUT
Mereo BioPharma
MREO
$50.4M
$81.2K 0.02%
39,400
– –
ATYR
123
PUT
aTyr Pharma
ATYR
$48.2M
$55K 0.01%
76,200
– –
FLNA
124
PUT
Filana Therapeutics
FLNA
$49.8M
$28.8K 0.01%
+9,900
New +$22.8K
KOD icon
125
PUT
Kodiak Sciences
KOD
$2.49B
$18K ﹤0.01%
+1,100
New +$9.48K
3 4
5
6 7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners deployed $27.8M of net new capital in Q3 2025, opening 75 new positions and adding to 15 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $5.86M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 49% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $10.2M trimmed.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.